Clinical Trial

ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss

Study acronym: ATARI
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
ATARI trial tests the ATR inhibitor drug ceralasertib (AZD6738) alone and in combination with either a PARP inhibitor drug called olaparib, or an anti-PD-L1 immunotherapy called durvalumab (MEDI4736) in patients with relapsed gynaecological cancers to assess the response in groups of patients selected based on their cancer cell subtype and the presence of an abnormality in the ARID1A gene.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2019-08-21; most recent amendment 2026-02-18.
Status change: Recruiting → Active, Not Recruiting 2026-02-18
Status change: Not Yet Recruiting → Recruiting 2019-11-26
Trial Details
NCT Number NCT04065269
Lead Sponsor Institute of Cancer Research, United Kingdom
Collaborators: Cancer Research UK, AstraZeneca
Conditions Gynaecological Cancers
Enrollment 174 participants
Start Date 2019-11-27
Primary Completion 2026-08 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2026-02-20